Compare Agnico Eagle Mines Ltd (AEM) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Heron Therapeutics Inc — how do they compare? Agnico Eagle Mines Ltd trades at $144.34 (market cap $75.10B), while Heron Therapeutics Inc trades at $0.43 (market cap $80.58M). The key difference: Agnico Eagle Mines Ltd is far larger — about 932× Heron Therapeutics Inc's market cap, and Agnico Eagle Mines Ltd pays a 1.2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AEM | HRTX | |
|---|---|---|
Market Cap | $75.10B | $80.58M |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $2.23 |
52-Week Low | $116.14 | $0.39 |
Enterprise Value | $72.30B | $178.48M |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
HRTX trades at $0.4339, down 1.03% today, with neutral technical signals and mixed earnings performance. The company reported a Q1 2026 loss of $0.04 per share, missing estimates, but maintains a strong gross margin of 71.12% and a low P/S ratio of 0.47. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite quarterly pressures.
Outlook remains speculative given persistent net losses and negative cash flow from operations, though analyst consensus is overwhelmingly bullish with 94.74% buy ratings. Key risks include execution challenges and competitive threats in the biotechnology sector, while potential upside hinges on achieving profitability and successful product commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
